Aurinia Pharmaceuticals (AUPH) – Research Analysts’ Weekly Ratings Updates

Aurinia Pharmaceuticals (NASDAQ: AUPH) recently received a number of ratings updates from brokerages and research firms:

• 8/20/2026 – Aurinia Pharmaceuticals was upgraded by Bloom Burton from “hold” to “strong-buy”.
• 8/12/2026 – Aurinia Pharmaceuticals had its “hold (c+)” rating reaffirmed by Weiss Ratings.
• 8/8/2026 – Aurinia Pharmaceuticals was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 8/7/2026 – Aurinia Pharmaceuticals had its price target raised by Royal Bank Of Canada from $15.00 to $16.00. They now have a “sector perform” rating on the stock.
• 7/21/2026 – Aurinia Pharmaceuticals was downgraded by Zacks Research from “strong-buy” to “hold”.
• 6/29/2026 – Aurinia Pharmaceuticals was upgraded by Zacks Research from “hold” to “strong-buy”.

Insider Activity at Aurinia Pharmaceuticals

In related news, CEO Kevin Tang acquired 343,620 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were acquired at an average cost of $15.28 per share, for a total transaction of $5,250,513.60. Following the completion of the purchase, the chief executive officer directly owned 12,838,101 shares in the company, valued at $196,166,183.28. This trade represents a 2.75% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders acquired 814,606 shares of company stock worth $12,455,129 over the last quarter. 10.40% of the stock is currently owned by company insiders.

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.